By Victor Reklaitis
The White House on Tuesday said it didn’t expect a big hit to the nationwide vaccination program after U.S. regulators recommended a pause in the use of Johnson & Johnson’s COVID-19 shots while they examine six cases of rare blood clots.
“This announcement will not have a significant impact on our vaccination plan,” said Jeff Zients, the White House’s COVID-19 response coordinator, in a statement .
J&J’s /zigman2/quotes/201724570/composite JNJ +0.45% one-shot vaccine makes up less than 5% of the shots in arms in the U.S. so far, according to Zients.
The Biden administration has secured enough doses of Pfizer’s /zigman2/quotes/202877789/composite PFE +1.00% vaccine and Moderna’s /zigman2/quotes/205619834/composite MRNA +1.65% vaccine for 300 million Americans, and it has made available more than 25 million doses of those products each week over the last few weeks, he added.
“This week we will make available 28 million doses of these vaccines,” Zients also said, referring to the shots from Pfizer and Moderna.
“This is more than enough supply to continue the current pace of vaccinations of 3 million shots per day, and meet the president’s goal of 200 million shots by his 100 day in office — and continue on to reach every adult who wants to be vaccinated.”
President Joe Biden echoed Zients in remarks made later Tuesday, saying the U.S. has enough vaccine “ for every single, solitary American .”
Biden last month rolled out a new goal for COVID-19 vaccinations, going for 200 million shots in arms by his 100th day in office , up from his initial goal of 100 million shots.
Zients on Tuesday also said the White House is working with its state and federal partners to get anyone scheduled for a J&J shot quickly rescheduled for a Pfizer or Moderna vaccine.
U.S. stocks /zigman2/quotes/210599714/realtime SPX +0.74% /zigman2/quotes/210598065/realtime DJIA +0.66% /zigman2/quotes/210598365/realtime COMP +0.88% were trading mixed Tuesday following the temporary halt for J&J’s jab.